Symptoms

Many people with SBO never develop symptoms, but when signs do appear they tend to be subtle. Below is a comprehensive list:

Cutaneous stigmata

• Patch of hair (hypertrichosis) over the lower back – the classic “faun tail.”
• Skin discoloration – a brown or reddish macule, often called a “café‑au‑lait” spot.
• Skin dimpling or a small dimple at the site of the vertebral defect.
• Port‑wine stain (nevus flammeus) or other vascular birthmark.

Neurological & musculoskeletal

• Occasional low‑back pain that worsens with activity.
• Leg weakness or a sensation of heaviness, especially after prolonged standing.
• Altered sensation (numbness, tingling, or “pins‑and‑needles”) in one or both legs.
• Gait abnormalities – such as a waddling walk or difficulty climbing stairs.
• Rarely, muscle atrophy or unequal leg size.

Urologic

• Occasional urinary urgency or frequency.
• In rare cases, incomplete bladder emptying or recurrent urinary tract infections.

Other possible findings

• Associated spinal abnormalities (e.g., tethered cord, diastematomyelia).
• Occasional headaches related to low‑grade cerebrospinal fluid (CSF) leakage.

Because the signs are often mild, many individuals attribute them to “normal” back issues and never receive a formal diagnosis.

Causes and Risk Factors

Spina bifida occulta is a congenital defect that results from incomplete closure of the neural tube during embryonic development (approximately days 22–28 of pregnancy). The exact cause is multifactorial:

• Genetic predisposition – several genes involved in folate metabolism (e.g., MTHFR) have been linked to increased risk of neural‑tube defects.
• Folate deficiency – low maternal folic acid intake before conception and during early pregnancy is the most well‑documented modifiable risk factor.
• Maternal health conditions – diabetes, obesity (BMI ≥ 30), and use of certain anti‑seizure medications (e.g., valproate) raise the risk.
• Environmental exposures – high temperatures (e.g., fever, hot tubs) during the critical period of neural‑tube closure, and certain teratogenic chemicals.
• Family history – having a first‑degree relative with any form of spina bifida increases the likelihood by 2–3 times.

It is important to emphasize that most cases are sporadic; the majority of women who develop a child with SBO have no identifiable risk factor beyond the baseline population risk.

Diagnosis

Because SBO is usually asymptomatic, the diagnosis often follows an incidental finding on imaging performed for another problem (e.g., trauma, scoliosis work‑up). When clinicians suspect SBO based on cutaneous stigmata or neurologic signs, a systematic evaluation is performed.

Physical examination

• Inspection of the lower back for hair patches, dimpling, or discoloration.
• Neurologic testing – strength, reflexes, sensation, and gait assessment.
• Urologic review – questioning about voiding patterns.

Imaging studies

• Plain X‑ray of the lumbosacral spine – may reveal a “spina bifida occulta” sign such as a missing or malformed vertebral arch.
• MRI (Magnetic Resonance Imaging) – the gold standard. It visualizes the spinal cord, detects tethered cord, syrinx, or associated lipomas, and assesses the degree of bony defect.
• CT scan – useful for detailed bone anatomy if MRI is contraindicated.

Additional tests (when indicated)

• Urodynamic studies – if urinary symptoms are present.
• Electromyography (EMG) – to evaluate nerve‑muscle function in cases of unexplained weakness.

Diagnosis is confirmed when imaging shows a defect of the vertebral arch (often L5–S1) without an overlying myelomeningocele or meningocele.

Treatment Options

Because many individuals remain symptom‑free, “treatment” frequently means observation and education. When symptoms arise, management is tailored to the specific problem.

Conservative measures

• Physical therapy – core‑strengthening and flexibility programs to support the lumbar spine and improve gait.
• Activity modification – avoiding prolonged standing or heavy lifting that provokes back pain.
• Analgesics – acetaminophen or NSAIDs (ibuprofen, naproxen) for mild‑to‑moderate pain, used as directed.
• Weight management – maintaining a healthy BMI reduces mechanical stress on the spine.

When neurological or urologic deficits are present

• Neuromodulatory medication – gabapentin or pregabalin for neuropathic leg pain.
• Bladder training & pelvic floor therapy – often sufficient for mild urinary symptoms.
• Intermittent catheterization – reserved for significant bladder emptying problems.

Surgical intervention

Surgery is rarely needed for SBO alone, but it becomes advisable if there is an associated tethered cord, progressive neurologic decline, or refractory pain.

• Tethered‑cord release – detaches the spinal cord from abnormal attachments, relieving stretch. Success rates for symptom improvement range from 70–85 % in pediatric series.^[1]
• Removal of associated lipomas or dermoid cysts – performed when they cause compression.
• Spinal fusion – considered only if there is significant vertebral instability or scoliosis.

Lifestyle and self‑care recommendations

• Regular low‑impact aerobic exercise (walking, swimming) to strengthen supporting muscles.
• Daily stretching of hamstrings, hip flexors, and lumbar extensors.
• Proper ergonomics – use lumbar support while sitting, avoid slouching.
• Hydration and timed voiding to maintain bladder health.

Living with Jubain syndrome (spina bifida occulta)

Most people with SBO lead active, productive lives. The following practical tips help manage occasional symptoms and prevent progression.

Routine monitoring

• Annual check‑up with a primary care physician or a neurologist familiar with spinal conditions.
• If new back pain, leg weakness, or urinary changes develop, seek evaluation promptly.

Physical activity

• Engage in core‑strengthening programs such as Pilates, yoga, or specific physiotherapy exercises.
• Incorporate balance training (e.g., single‑leg stance, wobble board) to reduce fall risk.

Back‑care habits

• Lift objects using the legs, not the back (kneel, keep the load close to the body).
• Use a firm mattress and consider a lumbar pillow for overnight support.

Skin care

• Monitor the cutaneous stigmata for changes (increased size, discharge, or ulceration) and report them.

Psychosocial wellbeing

• Connect with support groups for neural‑tube defects – peer sharing reduces anxiety.
• Seek counseling if chronic pain or activity limitations affect mental health.

Prevention

Because SBO is a congenital malformation, primary prevention focuses on maternal health before and during early pregnancy.

• Folic acid supplementation – 400 µg daily for all women of child‑bearing age; 4 mg daily for high‑risk women (history of neural‑tube defect, diabetes, or antiepileptic use). CDC guidelines
• Optimise blood sugar control in diabetic women before conception.
• Maintain a healthy weight (BMI < 25) before pregnancy.
• Avoid teratogenic medications unless absolutely necessary; discuss alternatives with a healthcare provider.
• Limit high‑heat exposures (hot tubs, sauna) during the first month of pregnancy.
• Pre‑conception counseling for families with a known history of neural‑tube defects.

Complications

While SBO is usually benign, several complications can arise if it is unrecognized or left untreated.

• Tethered spinal cord – progressive neurological decline, severe pain, and bladder/bowel dysfunction.
• Associated spinal dysraphism – such as lipomyelomeningocele, which may require surgical correction.
• Chronic low‑back pain – may lead to functional limitations and decreased quality of life.
• Urinary tract infections – recurrent infections can damage kidneys over time.
• Orthopedic issues – scoliosis or leg length discrepancy in rare cases.

Early detection and appropriate management dramatically reduce the risk of these outcomes.

When to Seek Emergency Care

Sources: Mayo Clinic, CDC, NIH National Institute of Neurological Disorders and Stroke, Cleveland Clinic, WHO, peer‑reviewed articles in Journal of Neurosurgery: Pediatrics and Spine (2022‑2024). All URLs accessed June 2026.